Skip to content

DrugPatentWatch - Transform Data into Market Domination

Business Intelligence on Biologic and Small Molecule Drugs

Blog Home
DrugPatentWatch Home
Pricing
About
Contact

DrugPatentWatch - Transform Data into Market Domination

Business Intelligence on Biologic and Small Molecule Drugs

Blog Home
DrugPatentWatch Home
Pricing
About
Contact

Drug Patent Expirations for the Week of September 6, 2026

By / September 8, 2026

Copyright © DrugPatentWatch. Originally published at https://www.drugpatentwatch.com/blog/

RYTELO (imetelstat sodium)

Geron Patent: 9,388,415 Expiration: Sep 9, 2026

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

» Start Your Free Trial Today «

Copyright © DrugPatentWatch. Originally published at

Related Posts:

The Price Control Playbook: A Strategic Analysis of…
Unlocking the Potential of Abandoned and Expired…
Using Drug Patents to Block Competitors: The Tactics…
The Strategic Imperative: Unlocking Latent Value in…
Predict The Patent Cliff: The Patent Cliff Is…
Patent Expiration Data: The Procurement Playbook…
Mine the Orange Book: How FDA Drug Patent Data…
How Financial Analysts Use Drug Patent Expiry Data…
Build a Live Drug Patent LOE Dashboard Your…
Patent Expiration Dates: The Calendar Every…
Patent Expiration Intelligence: The GPO Contract…
Patent Citations: The Recruiter's Guide to Finding…
How to Search Drug Patents: The Competitive…
The Patent Cliff Playbook: A Strategic Guide for…
A Strategic Playbook for Timing ANDA Submissions…
Addressing the Challenges of Pharmaceutical…
Beyond Clinical Trials: Why Drug Patent Portfolios…
The Global Patent Thicket: A Comparative Analysis of…
The Global Generic Drug Market: Trends,…
Free Patent Databases Are Costing Pharma Teams $10K…
Valuation Volatility: The Pharma Investor’s…
Your Drug's Patent Expired. Now What? The Complete…
Designing Around the Moat: A Generic Developer's…
The Repurposing Revolution: Unlocking Hidden Value…

The Compulsory License Nobody Expects Until a Government Invokes It

Related Posts

Drug Patent Expirations for the Week of January 4, 2026

Patent Expiration / By

Drug Patent Expirations for the Week of January 18, 2026

Patent Expiration / By

Make Better Decisions

See Plans & Pricing

Recent Posts

The Compulsory License Nobody Expects Until a Government Invokes It
Your US Patent Strategy Doesn’t Translate to India. That Gap Is Where the Supply Chains Get Built.
Your Global Launch Sequence Assumes Uniform Patent Life. That Assumption Costs Market Share.
You Found the Patent. Did You Find the Company That Owns It?
The Patent Owner on Your Screen May Not Own the Patent Anymore

Popular Posts

The Unbundling of the Apothecary: How Vertically Integrated Telehealth Is Dismantling the Pharmaceutical Value Chain
How Long Does a Drug Patent Actually Last? The Definitive Analyst’s Guide to Pharmaceutical Patent Duration, Term Extension Mechanics, Regulatory Exclusivity Stacking, and Effective Market Exclusivity Calculation
Pharmaceutical Licensing Agreements: The Complete IP Valuation, Deal Architecture, and Strategy Guide for Pharma/Biotech Leaders
The Drug Name Decoder: A Complete Guide to Generic Pharmaceutical Naming
Generic Drug Market: The Complete IP, Regulatory & Investment Playbook
Lipitor’s Patent Cliff Playbook: How Pfizer Kept 40% Market Share After Generic Entry — and What It Means for Your LOE Strategy
Branded Generics and Why They’re Profitable
Maximizing Pharmaceutical Patent Longevity: A Mechanistic and Strategic Guide to IP Term Extension and Lifecycle Fortification
The Challenger’s Playbook: 9 Ways Generic Drug Companies Turn Patent Litigation into Market Victory
Freedom to Operate in Pharma: The Step-by-Step FTO Analysis That Protects Your Pipeline

Copyright © 2026 DrugPatentWatch - Transform Data into Market Domination

DrugPatentWatch - Transform Data into Market Domination

Subscribe to Free Updates

Sign in or create a free account to read this DrugPatentWatch article

Sign in or create a free account to read this DrugPatentWatch article

EmailEnter your email address